key: cord-0872198-9z0pwde3
authors: Aydin, Mehmet Fethullah; Yildiz, Abdulmecit; Oruc, Aysegul; Sezen, Mehmet; Dilek, Kamil; Gullulu, Mustafa; Yavuz, Mahmut; Ersoy, Alparslan
title: Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination
date: 2021-05-13
journal: Kidney Int
DOI: 10.1016/j.kint.2021.05.001
sha: 6c06538d222853481f2e4d931750be7c4f34a8f1
doc_id: 872198
cord_uid: 9z0pwde3

nan

To the editor:

Coronavirus disease 2019 (COVID-19) vaccine is one of the most effective public health interventions to end the COVID-19 outbreak. There are insufficient data on the use of COVID-19 vaccines in patients with autoimmune disease, but vaccines appear to be safe, and experience from previous vaccine studies does not indicate an increased risk of relapse/recurrence. 1 However, theoretically, unwanted immunological events such as autoimmunity may be triggered by vaccines. We report a patient with membranous nephropathy (MN) that stayed in remission for eight years and experienced a relapse after vaccination with a purified inactivated SARS-CoV-2 virus vaccine called CoronaVac infections, and drugs were excluded, but anti-phospholipase A2 receptor (anti-PLA2R) antibody could not be tested since it was not available. She was treated with steroid, cyclosporine, and lisinopril 10 mg/day. Complete remission was achieved within three months, and all immunosuppressive treatments were discontinued at six months while lisinopril 10 mg/day was continued. Renal functions and urinary protein excretion remained in the normal range without immunosuppressive therapy for eight years. Her medical history also showed hypertension for one year, diabetes mellitus and hyperlipidemia for six years. On admission, urea was 93 mg/dL, creatinine 2.78 mg/dL, serum albumin 2.6 g/dL, spot urine protein creatinine ratio 9.42 mg/mgCr and anti-PLA2R antibody was positive (120.53 RU/mL [<14 negative, >20 positive]). Secondary causes of MN such as malignancy, infections, and drugs were excluded. No diabetic retinopathy was noted. A diagnosis of MN relapse was established given the clinical symptoms and laboratory examination results.

To our knowledge, cases of nephrotic syndrome in MN form have been reported after influenza vaccination. 2,3 A case of minimal change disease with full-blown nephrotic sydrome and AKI ten days after the Pfizer-BioNTech COVID-19 vaccination has also been reported. 4 In addition to this case we observed two patients developed anti-PLA2R positive MN after SARS-CoV-2 infection. Our observation suggests that the SARS-Cov-2 virus may cause a loss of tolerance to PLA2R antigen. Consequently close follow-up of patients with MN after SARS-CoV-2 vaccination is recommended. Further studies are need to determine

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association

Can influenza H1N1 vaccination lead to the membranous glomerulonephritis? Indian journal of pathology & microbiology

Membranous nephropathy and severe acute kidney injury following influenza vaccination. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine